Ad chides Gilead "greed" over Sovaldi pricing

Share this article:

The AIDS Healthcare Foundation (AHF) took out an ad in today's Wall Street Journal blasting Gilead and “our state and federal leaders,” whom the coalition charges with “breaking the bank by paying whatever Gilead and its pharma allies demand without question.”

The half-page, four-color ad was slated to run in WSJ editions in Northern California and the Washington/Maryland/Virginia markets, AHF said, coinciding with Gilead's Annual General Meeting in Millbrae, CA.

The headline of the ad reads:


The nonprofit AIDS organization has been a frequent critic of drug pricing and has been vocal before.

In January, the group's leader—Michael Weinstein—also referred to Gilead's HIV prevention treatment, Truvada, as a “party drug,” amid reports from the New York Times about the drug's stigma in the gay community.  

And in 2007 the group went so far as to file a suit with Pfizer over its DTC campaign for ED drug Viagra. AHF accused Pfizer of promoting recreational use of Viagra and suggested a link between the drug and illicit methamphetamine use. A Pfizer spokesperson at the time denied the claims and added that AHF had approached the company, “with a multimillion-dollar funding request for a crystal meth educational program.”

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Reimagining healthcare? We want to hear about it.
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters


More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.